LBI-HTA - Publications - Search - Enzalutamide (Xtandi®) for patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy

Breuer, J. and Nachtnebel, A. (2013): Enzalutamide (Xtandi®) for patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy . DSD: Horizon Scanning in Oncology 37.

[img]PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
444Kb
Abstract

Metastatic castration-resistant prostate cancer (mCRPC) poses a major clinical challenge although treatment options have improved over the last years. Enzalutamide is an oral second generation androgen receptor (AR) inhibitor reducing prostate cell proliferation and prostate specific antigen (PSA) levels by targeting multiple steps in the AR signalling pathway. For patients with mCRPC who experience disease progression after initial therapy with docetaxel the U.S. Food and Drug Administration (FDA) licensed enzalutamide in August 2012.
In a phase III trial, enzalutamide was compared to placebo in 1,199 docetaxel-refractory patients. The primary endpoint was overall survival (OS). Secondary endpoints included radiographic progression-free survival, time to PSA progression or quality of life. For patients treated with enzalutamide OS was extended by 4.8 months. All secondary endpoints were also improved in the intervention group.
Besides cabazitaxel and abiraterone acetate, enzalutamide is the third agent for mCRPC patients previously treated with docetaxel-based chemotherapy. Differences in administration (enzalutamide and abiraterone acetate are taken orally while cabazitaxel is administered intravenously) may influence therapy decisions, but further clinical trials comparing these active agents with each other, and not with placebo are needed.

Item Type:DSD: Horizon Scanning in Oncology
Keywords:metastatic prostate cancer, enzalutamide, Xtandi®, oncology, castration-resistant
Subjects:WB Practice of medicine > WB 300-962 Therapeutics
WJ Urogenital system > WJ 140-160 Urologic diseases
WJ Urogenital system > WJ 700-875 Male genitalia
QZ Pathology > QZ 200-380 Neoplasms.Cysts
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Language:English
Series Name:DSD: Horizon Scanning in Oncology 37
Deposited on:07 Jun 2013 18:11
Last Modified:29 Nov 2013 13:19

Repository Staff Only: item control page